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Introduction
Although the incidence of cancer increases in the eld-
erly, some tumors appear to grow more slowly in older
patients compared to younger patients. For exam-
ple, lung cancer was found to be more frequently in an
advanced stage and with a worse prognosis in younger
patients than in older patients.1–5 The underlying
mechanism of this clinical finding is unknown.
B16-F10 (B16) melanoma is a melanoma cell line
derived from C57BL/6 (B6) mice. The use of pul-
monary metastasis models with B16 melanoma and
B6 mice is a well-documented method to study ways
of enhancing anti-tumor immunity.6,7 Cytokines, such
as interleukin (IL)-2 and IL-12, have been found to
be involved in cellular immunity, and play an important
role in anti-tumor immunity.8–12 We have also found
that IL-2 plus IL-12 can restore the cytotoxic func-
tion of immunosuppressed lymphocytes isolated from
malignant pleural effusion, and IL-2 plus IL-12 can
also enhance B6 mice immunogenicity against the
pulmonary metastases of B16 melanoma.6,10 This work
used B6 mice and an intravenous injection (IV) of B16
melanoma tumor cells as a model to study whether or
not B16 melanoma tumor cells had higher tumori-
genicity in young mice than in middle-aged mice, and
whether or not immunotherapy had different efficacy
in young and middle-aged tumor-bearing mice. The
results showed that the younger mice suffered from
more severe pulmonary metastases and poorer survival
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than the middle-aged mice after IV of B16 melanoma
cells. An IV of IL-2 plus IL-12 prolonged the survival
of both the younger and older tumor-bearing mice,
but cure was not possible.
Methods
Mice
Permission was obtained from the experimental ani-
mal protocol review board of our institution. Female
C57BL/6 (B6) mice, 3–4 weeks old, were purchased
from the Veterinary Resource Center, National Science
Council, Taiwan. The mice were used for experiments
at the age of 1 month as young mice, or raised up 
to 24 months old and used at different ages. The 12-
month-old mice were used as middle-aged mice.
Melanoma cell preparation
The tumor cell line used in the study was the B16-F10
(B16) melanoma cell line. The cells were maintained
in vitro in RPMI-1640 supplemented with 10% fetal
bovine serum (GIBCO, Grand Island Biological Co.,
Grand Island, NY, USA), 2 mM glutamine (GIBCO),
50 μg/mL streptomycin and 500 U/mL penicillin.
Cytokines
Recombinant human IL-2 and mice IL-12 were pur-
chased from R&D Systems, Inc. (Minneapolis, MN,
USA). Daily intraperitoneal injections (IPs) of IL-2
2,000IU/mouse and IL-12 100 μg/mouse were given
at different durations of time for immunotherapy. 
For the in vitro study, IL-2 300 IU/mL and IL-12
10 ng/mL were used for the splenocyte culture and
stimulation test.
Pulmonary metastasis model
For the pulmonary metastasis model, IV of single cell
suspensions of 5 × 105 B16 tumor cells were admini-
stered into the lateral tail vein of each mouse. Within
21 days after tumor injection, grossly visible metas-
tases were present on the surface of the lungs of 
the normal mice injected with tumor cells. These pul-
monary metastases were confirmed by histologic
examinations.
In vitro cytotoxicity assay
An overnight (18 hours) 51Cr release assay was per-
formed, using B16 and P815 cells as targets. The effec-
tor cells were splenocytes isolated from sacrificed mice.
Target cells were labeled with Na251CrO4 (Amersham,
Buckinghamshire, England) for 90 minutes. Different
volumes of effector cells and 50 μL of 51Cr-labeled 
target cells (5 × 103) were assigned at effector:target cell
ratios of 100:1, 30:1 and 10:1 to the wells of round-
bottomed microtiter plates (Nunc, Roskilde, Denmark)
in triplicate, and were incubated overnight at 37°C in
a humidified 5% CO2 incubator. After incubation, the
supernatant was harvested, and radioactivity was
counted using a gamma scintillation counter. The
spontaneous 51Cr release was determined by the incu-
bation of target cells without the effectors, and maxi-
mal release was determined by counting 50 μL of the
51Cr-labeled target cells. The percentage of cytotoxicity
was determined using the following formula (where
cpm = counts per minute):
One lytic unit (LU) was defined as the number of
effectors required to give 30% lysis (specific or net %
lysis) of 5×103 target cells. The cell line, P815, a murine
mastocytoma cell line, was used as the control tumor
target in the cytotoxicity assay.
Determination of proliferative response
Cultured splenocytes at 0.1mL were dispensed into 96-
well flat-bottom microplates in triplicate. 3H-thymidine
at 2 μCi/mL was added to each well, and the cells were
incubated overnight at 37°C in a humidified 5% CO2
incubator. The incorporation of 3H-thymidine was
determined using a β-plate counter after the incu-
bated cells were harvested using a cell harvester. The
results were expressed as CPM±SEM (mean counts per
minute ± standard error of the mean).
Enzyme-linked immunosorbent assay 
(ELISA) analysis of cytokine levels
The blood samples collected from direct cardiac punc-
tures in the sacrificed mice of the various groups were
centrifuged at 4°C, and the supernatants were collected
and stored at −70°C in microcentrifuge tubes. IL-10,
interferon-γ (IFN-γ) and vascular endothelial growth
factor (VEGF) were determined in duplicate using 
a solid-phase ELISA method that employed the quan-
titative “sandwich” enzyme immunoassay technique
(Quantikine; R&D Systems, Inc.). Positive and nega-
tive controls were included in the assay.
Statistical analysis
The 2-tailed Mann–Whitney U test was used to evaluate
the statistical difference in the number of pulmonary
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=
−
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metastases seen on the surface of the lungs of the
tumor-bearing mice, cytolytic and proliferative activity
of cultured splenocytes, and cytokine levels of the
serum from sacrificed mice. Scheffe’s post hoc test was
performed for multiple comparisons. For survival analy-
sis in the pulmonary metastasis model, the Kaplan–
Meier method and log–rank test were used.
Results
There was poorer survival in young tumor-bearing
mice compared to middle-aged tumor-bearing mice,
and survival could not be prolonged with 3-day treat-
ment of IL-2 plus IL-12. Twenty-nine female mice
were classified into 4 groups, including 6 young mice
that received B16 melanoma IV on day 0, 6 young
mice that received B16 melanoma IV on day 0 and
daily IL-2 and IL-12 IP from day 0 to day 2, 9 middle-
aged mice that received B16 melanoma IV on 
day 0, and 8 middle-aged mice that received B16
melanoma IV on day 0 and daily IL-2 and IL-12 IP
from day 0 to day 2. Survival analysis (Figure 1) showed
that middle-aged mice suffering from pulmonary
metastases without cytokine treatment had better sur-
vival than young mice suffering from pulmonary metas-
tases without cytokine treatment (median survival 25
vs. 20 days, p = 0.0003). Three days of treatment with
IL-2 plus IL-12 could not prolong mice survival
(median survival was 20 days in both groups of young
mice and 25 days in both groups of middle-aged mice).
Eleven days of IL-2 plus IL-12 treatment 
prolonged mice survival
Fifty-eight female mice were classified into 4 groups,
including 14 young mice that received B16 melanoma
IV on day 0, 15 young mice that received B16
melanoma IV on day 0 and daily IL-2 and IL-12 IP
from day 0 to day 10, 15 middle-aged mice that
received B16 melanoma IV on day 0, and 14 middle-
aged mice that received B16 melanoma IV on day 0
and daily IL-2 and IL-12 IP from day 0 to day 10.
Eight mice were sacrificed on day 5 and another 8 mice
were sacrified on day 9 for microscopic examination and
serum collection. Eighteen mice were sacrificed on day
14 in order to count the number of pulmonary metas-
tases on the surface of the lungs and to perform histo-
logic examination. The remaining mice were allowed
to survive until their death, for survival analysis.
The overnight splenocyte proliferation assay (with-
out adding mitogen or cytokine into the culture
medium) performed on the splenocytes retrieved on
days 5 and 9 from the sacrificed mice showed that the
proliferative activity of the splenocytes from the tumor-
bearing mice was lower than that of the splenocytes
from the normal control mice. The mice treated with
IL-2 and IL-12 had a splenocyte proliferative response
similar to that of the normal control mice that were
sacrificed on day 5 (day-5 mice), but this response
was reduced again in the splenocytes from the mice
sacrificed on day 9 (day-9 mice) (Figure 2).
The cytolytic activity of the splenocytes from the
sacrificed normal mice and from the tumor-bearing
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Figure 1. The survival curve of B6 mice with/without 3 days of interleukin (IL)-2 and IL-12 treatment. The overall survival showed that
middle-aged mice suffering from pulmonary metastases without cytokine treatment had better survival than young mice suffering from
pulmonary metastases without cytokine treatment (median 25 vs. 20 days, p = 0.0003). Three days of IL-2 plus IL-12 treatment could
not prolong mice survival.
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mice with/without daily IL-2 and IL-12 treatment that
were sacrificed on days 5 and 9, against B16 melanoma
cells and P815 cells, was very low, with LU < 1.
However, when the splenocytes retrieved from the
day-5 tumor-bearing mice that had been treated daily
with IL-2 and IL-12 were cultured in medium con-
taining IL-2 and IL-12 for 4 more days, their cytolytic
activity against B16 cells and P815 cells was markedly
increased (Figure 3). This cytolytic activity was rela-
tively more specific to the B16 melanoma cells in
those splenocytes from cytokine-treated tumor-bearing
mice that were further cultured with IL-2- and IL-12-
containing medium for 4 more days than the spleno-
cytes from normal mice that were cultured with
medium containing IL-2 and IL-12 (Figure 3).
A counting of the number of lung surface metas-
tases in the mice that had been sacrificed on day 14
(day-14 mice) showed that the young tumor-bearing
mice had the highest number of metastases, followed
by the middle-aged tumor-bearing mice. Eleven days’
treatment with IL-2 plus IL-12 reduced the number
of metastases in the young tumor-bearing mice to a
degree less than that in the middle-aged tumor-bearing
mice without cytokine treatment. Middle-aged tumor-
bearing mice treated with IL-2 plus IL-12 had the least
number of metastases (Table 1). In addition to the
difference in the number of lung surface metastases,
the size of the metastatic lesions was smaller in the
middle-aged mice than in the young mice, as well as
in the cytokine-treated tumor-bearing mice compared
to those without cytokine treatment.
Regarding survival, the middle-aged tumor-bearing
mice without cytokine treatment consistently survived
longer than the young tumor-bearing mice without
cytokine treatment (p = 0.0006), as in part 1 of the
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Figure 2. Overnight proliferation assay of splenocytes retrieved from each group of mice sacrificed on days 5 and 9. The proliferative
activity of splenocytes from tumor-bearing mice was lower than that of normal control mice; interleukin (IL)-2- and IL-12-treated tumor-
bearing mice had a proliferative response similar to the normal control mice on day 5, but that decreased again on day 9. *p < 0.05.
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Figure 3. Cytolytic activity of cultured splenocytes against B16 cells
and P815 cells. A = splenocytes retrieved from young normal mice
and cultured with interleukin (IL)-2- and IL-12-containing medium
for 4 days. B = splenocytes retrieved from middle-aged normal mice
and cultured with IL-2- and IL-12-containing medium for 4 days. 
C = splenocytes retrieved from young tumor-bearing mice that had
been treated daily with intraperitoneal injections (IPs) of IL-2 and
IL-12 and sacrificed on day 5, then cultured with IL-2- and IL-12-
containing medium for 4 more days. D = splenocytes retrieved from
middle-aged tumor-bearing mice that had been treated daily with
IPs of IL-2 and IL-12 and sacrificed on day 5, then cultured with IL-2-
and IL-12-containing medium for 4 more days. When splenocytes
isolated from the day-5 tumor-bearing mice that had been treated
daily with IPs of IL-2 and IL-12 continued to be cultured in medium
containing IL-2 and IL-12 for 4 more days, their cytolytic activity
against B16 cells and P815 cells was markedly increased.
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experiment. Eleven days’ treatment with IL-2 plus
IL-12 significantly prolonged the survival of both the
young and middle-aged tumor-bearing mice (p=0.0006
and 0.0022, respectively); the cytokine-treated mid-
dle-aged tumor-bearing mice also survived significantly
longer than the cytokine-treated young tumor-bearing
mice (p = 0.0041) (Figure 4).
Maintenance therapy with IL-2 and IL-12 did
not increase tumor-bearing mice survival
The experiment was then extended to include long-
term IL-2 plus IL-12 treatment, including 7 young
mice that received B16 melanoma IV on day 0, 5 young
mice that received B16 melanoma IV on day 0 and
daily IL-2 and IL-12 IP from day 0 to day 2, 10 young
mice that received B16 melanoma IV on day 0 and daily
IL-2 and IL-12 IP from day 0 to day 10, then, 3 times
weekly for 3 weeks, 10 young mice that received B16
melanoma IV on day 0 and daily IL-2 and IL-12 IP
from day 0 to day 10, then, every day except Sunday,
for 3 weeks, 7 middle-aged mice that received B16
melanoma IV on day 0, 7 middle-aged mice that
received B16 melanoma IV on day 0 and daily IL-2
and IL-12 IP from day 0 to day 2, 11 middle-aged
mice that received B16 melanoma IV on day 0 and
daily IL-2 and IL-12 IP from day 0 to day 10, then, 
3 treatments weekly for 3 weeks, and 11 middle-aged
mice that received B16 melanoma IV on day 0 and daily
IL-2 and IL-12 IP from day 0 to day 10, then, every
day except Sunday for 3 weeks. Survival analysis again
showed that the middle-aged tumor-bearing mice had
better survival than the young tumor-bearing mice; 3
Table 1. Number of lung surface metastases in day-14 sacrificed mice*
Group (number of mice) Mean ± SEM Median (range) p
Young tumor-bearing mice (4) > 200 > 200
Young tumor-bearing mice + IL-2 + IL-12d 0–10 (5) 20.9 ± 2.4 19 (7–39) < 0.001†
Middle-aged tumor-bearing mice (5) 31.6 ± 3.2 26 (18–64) < 0.001†
0.011‡
Middle-aged tumor-bearing mice + IL-2 + IL-12d 0–10 (4) 6.7 ± 1.4 6 (0–16) < 0.001†
< 0.001‡
< 0.001§
*Three investigators blindly and independently counted the number of lung surface metastases in these mice; †when compared with young tumor-bearing
mice; ‡when compared with young tumor-bearing mice + IL-2 + IL-12d 0–10; §when compared with middle-aged tumor-bearing mice. Scheffe’s post hoc test
showed there was significant difference between these groups. SEM = standard error of the mean; IL = interleukin; d = days.
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Figure 4. Eleven days of interleukin (IL)-2 plus IL-12 treatment prolonged both the young and middle-aged tumor-bearing mice’s survival sig-
nificantly, and the survival of the middle-aged cytokine-treated tumor-bearing mice was significantly better than that of the young cytokine-
treated tumor-bearing mice. Six mice were included in each group, including young tumor-bearing mice, young tumor-bearing mice that
received cytokine treatment, middle-aged tumor-bearing mice and middle-aged tumor-bearing mice that received cytokine treatment.
Intravenous injection of B16 melanoma on day 0 was administered to produce tumor-bearing mice. Cytokine treatment included intraperi-
toneal injections of IL-2 plus IL-12 once daily from day 0 to day 10. Median survival was 21, 30, 26 and 35 days for each group, respectively.
p = 0.0006 for group 1 vs. group 2; p = 0.0006 for group 1 vs. group 3; p = 0.0022 for group 3 vs. group 4; p = 0.0041 for group 2 vs. group 4.
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days’ treatment with IL-2 plus IL-12 did not prolong
survival, as a previous study has demonstrated, but
long-term maintenance therapy with IL-2 plus IL-12
did improve the mice’s survival. However, this
improvement in survival was not better than that of
the mice that received 11 days’ treatment (data not
shown).
Similar experimental results with 3- and 
1-month-old mice, and with 2- and 
1-year-old (middle-aged) mice
The studies were extended to test 3-month-old mice,
1-year-old mice and 2-year-old mice to determine
whether or not the abovementioned findings were
similar between 1- and 3-month-old mice, and between
1- and 2-year-old mice. The results showed that the
2-year-old tumor-bearing mice had a borderline longer
survival than the 1-year-old tumor-bearing mice (p =
0.065), and the 3-month-old tumor bearing mice had
a poorer survival than the 1- and 2-year-old mice (each
group had 6 mice, p = 0.018). Eleven days’ IL-2 plus
IL-12 treatment prolonged their survival significantly
(each group had 5 mice) compared to the tumor-
bearing mice without cytokine treatment. Another 4
mice from each group of tumor-bearing mice with/
without cytokine treatment were sacrified on day 14
in order to count the number of pulmonary metas-
tases on the surface of the lungs. The results for 
the 3-month-old mice were similar to those for the 
1-month-old mice mentioned above, and the results
for the 2-year-old mice were similar to those for the 
1-year-old mice mentioned above, in both the tumor-
bearing mice and the tumor-bearing mice with cytokine
treatment (data not shown).
Cytokine analysis
The serum from normal young mice had higher IL-10
and IFN-γ levels than that from normal middle-aged
mice. Serum IL-10 levels were significantly elevated after
the mice had suffered from pulmonary metastases for
7 days, while the change in serum IFN-γ levels was less
marked. After 7 days’ IP of IL-2 plus IL-12 were
given daily, the normal young mice had markedly ele-
vated serum IFN-γ, while the increase in the middle-
aged normal mice was less marked. When the mice
suffered from pulmonary metastases and were treated
daily with IL-2 plus IL-12, the increase in serum IFN-γ
was much less than that of the normal mice without
pulmonary metastases and treated with IL-2 and IL-
12. When normal mice were treated with IL-2 plus
IL-12, the serum IL-10 levels decreased in the young
mice, and showed no obvious change in the middle-
aged mice. When the mice that were suffering from
pulmonary metastases were treated with IL-2 plus IL-
12, their serum IL-10 levels were lower than those of
both the young and middle-aged tumor-bearing mice
that were not cytokine-treated. These results meant
that the B6 mice had IL-10 and IFN-γ ratios that
were in favor of the Th-2 pathway when in a normal
condition, and that shifted even more when the mice
were suffering from pulmonary metastasis. IL-2 and
IL-12 treatment could drive the pathway in a Th-1
direction. All these cytokine levels and changes in level
were more marked in the young mice than in the
middle-aged mice (Figure 5).
In terms of VEGF, both the normal young and
middle-aged mice had similar serum levels. However,
when the mice suffered from pulmonary metastasis
with/without IL-2 plus IL-12 treatment, the middle-
aged mice had elevated VEGF levels compared to the
normal middle-aged mice with/without IL-2 plus
IL-12 treatment (Figure 5C). However, this elevation
in the middle-aged mice’s serum VEGF levels compared
to the young mice’s levels was statistically insignificant
(p > 0.05), either with/without pulmonary metastases
or with/without IL-2 and IL-12 treatment.
Discussion
Cancer incidence increases with age. However, the
growth and spread of tumors is often slow and pro-
longed in the elderly. Transplantable murine tumors
grow and spread less readily in older mice, and can be
used as models to study the effect of host age.7,13,14
Neovascularization is crucial for the growth of solid
tumors, and alterations in host vascular response may
underlie the changes in tumor growth that occur with
age. It has been found that tumor growth in older
animals is associated with less formation of new blood
vessels, and this may explain the slower tumor growth
observed in aged animals with certain experimental
tumors.13,14 The elevated serum VEGF levels in the
older tumor-bearing mice in this study probably reflect
the presence of low levels of VEGF receptors that
uptake VEGF in the lungs of the older mice, and thus
the older tumor-bearing mice were unable to develop as
many new tumor-associated vessels as in the young mice.
Although some studies have researched the influ-
ence of age on pulmonary metastasis, there has been no
report on the effect of cytokine immunotherapy on
tumor-bearing mice in different age groups, as in the
present study. The results of our study show that the
splenocyte proliferative response was decreased in both
day-5 and day-9 young and middle-aged tumor-bearing
mice compared with the splenocyte response in normal
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mice (Figure 2), while daily IL-2 and IL-12 treatment
could reverse this tumor-induced immunosuppressive
splenocyte proliferative response in the day-5 mice.
However, the stimulating effect of daily IL-2 plus IL-
12 treatment on splenocytes was surpassed by the
tumor-induced immunosuppressive effect on day 9,
when there was greater tumor burden on the mice.
This improvement in the proliferative response of the
splenocytes in the day-5 tumor-bearing mice brought
about by IL-2 plus IL-12 IP implies that these cytokine
treatments did have some effect on the mice’s lym-
phocyte function against tumor cells. However,
cytolytic activity against B16 tumor cells was still not
activated, and was very low in the splenocytes isolated
from the day-5 and day-9 tumor-bearing mice that
had been treated daily with IL-2 and IL-12 IP. In
contrast, the cytolytic activity of the day-5 splenocytes
was markedly increased after they were cultured with
medium containing IL-2 and IL-12 for 4 more days,
and this cytolytic activity was relatively specific to 
B16 melanoma cells compared to P815 tumor cells
(Figure 3), suggesting that relatively tumor-specific
killer cells had been formed or primed in the spleens of
the tumor-bearing mice. In addition, activated spleno-
cytes from the young mice had higher cytolytic activity
than the activated splenocytes from the middle-aged
mice (Figure 3), and the recovered splenocyte prolif-
erative response was better in the day-5 tumor-bearing
young mice that had been treated with IL-2 plus IL-
12 than in the day-5 tumor-bearing middle-aged mice
that had been treated with IL-2 plus IL-12 (Figure 2),
implying that the young mice had better cellular
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Figure 5. (A) Interferon (IFN)-γ; (B) interleukin (IL)-10; and (C) vascular endothelial growth factor (VEGF) levels in the serum of the mice sac-
rificed on day 7. At least 5 mice from each group of the normal young and middle-aged mice, tumor-bearing young and middle-aged mice,
normal young and middle-aged mice treated daily with IL-2 plus IL-12 from day 0 to day 7, and tumor-bearing young and middle-aged mice
treated with IL-2 plus IL-12 from day 0 to day 7, were sacrificed on day 7. Their sera were collected for ELISA. The normal young mice had
higher IL-10 levels than the middle-aged mice, and both groups of mice had even higher IL-10 levels when suffering from pulmonary metas-
tases, while IFN-γ showed no obvious change. IL-2 plus IL-12 treatment in the normal young mice increased IFN-γ levels significantly. When
tumor-bearing mice were treated with IL-2 plus IL-12, IL-10 levels decreased to a level less than that of the tumor-bearing mice without
treatment. Serum VEGF was elevated in the middle-aged mice suffering from pulmonary metastases. *p < 0.05.
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immunity than the middle-aged mice when suffering
from malignant disease.
The results of the serum cytokine profiles (IFN-γ
and IL-10) suggest that normal mice are usually within
or in favor of the Th-2 pathway (IL-10 levels higher
than IFN-γ) under normal conditions, and that the
situation worsens (elevation of IL-10, with the path-
way driven further in the Th-2 direction) when the
mice suffer from B16 pulmonary metastasis. IL-2 and
IL-12 treatment could drive this pathway in the Th-1
direction (increased IFN-γ and decreased IL-10).
Similar to the findings on splenocyte cellular function
(proliferation and cytolytic activity), the data of these
cytokine levels and their changes were more marked
in the young than in the middle-aged mice.
Our findings showed that there was a poorer sur-
vival in the young tumor-bearing mice compared to
the older tumor-bearing mice, and survival could not
be prolonged with 3 days’ treatment with IL-2 plus
IL-12. However, IL-2 plus IL-12 IP for 11 days could
prolong mice survival. Unfortunately, prolongation of
IL-2 plus IL-12 treatment by another 3 weeks did not
increase survival. The lack of efficacy of short-term
cytokine treatment in prolonging tumor-bearing mice
survival was most likely due to the inadequate treat-
ment duration, which was too short to see treatment
effects. In contrast, the underlying cause of the failure
of long-term cytokine maintenance treatment to pro-
long tumor-bearing mice survival, as compared to the
11-day cytokine treatment, was probably due to the
inability to completely inhibit pulmonary metastasis
from the beginning, resulting in continuous tumor
growth despite cytokine treatment, and the tumor
growth surpassing the cytokine function and trigger-
ing profound tumor-induced immunosuppression,
probably after 10 days of cytokine treatment. Thus,
IL-2 plus IL-12 treatment could only delay and ini-
tially decrease tumor-induced immunosuppression.
Another issue is that prolonged cytokine treatment
may be very toxic to mice, especially young mice,
because of the progressive decrease in the weight of
many mice during the treatment. In addition, the study
was extended to include 3-month-old and 2-year-old
mice to demonstrate the effect of aging on host response
to tumors and the immunotherapy. The results were
similar between the 1- and 3-month-old mice, as well
as between the 1- and 2-year-old mice.
Silagi et al15 reported that high-dose IL-2 (50,000
IU/mouse) and IFN-γ (5–15 μg/mouse) IPs every
other day could cure about half of the B6 mice that
received B16 tumor IP. The main difference between
their study and this one was that their study was more
likely an in vivo tissue culture situation with the addition
of tumor cells, local high cytokine concentrations, and
close interaction of tumor and immune cells within
the peritoneal cavity, while this study was a distant
metastasis model in which the tumor burden in the
lung was high, and the cytokine levels that were used to
research the pulmonary circulation or the lung were
low. There was also less close interaction between the
tumor and immune cells in this study. Thus, immuno-
therapy with IL-2 and IL-12 was found to be less useful
in this study, similar to Silagi et al’s finding that the
effect of local treatment on a localized tumor was supe-
rior to systemic or distant treatment. However, this
study model is closer to the actual clinical situation in
which disseminated tumors usually cannot be cured by
immunotherapy, and immunotherapy can only reduce
the tumor burden temporarily.
In summary, the young mice had more severe pul-
monary metastases and poorer survival than the older
mice when both were challenged with intravenous
tumor injections, despite the fact that the young mice
had better cytokine and cellular immune function.
Cytokine treatment with IL-2 and IL-12 could improve
both groups’ survival, but the older mice still survived
longer than the younger mice.
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